利妥昔单抗用于特发性膜性肾病治疗的研究进展
Research Progress of Rituximab in the Treatment of Idiopathic Membranous Nephropathy
DOI: 10.12677/ACM.2023.132210, PDF,    科研立项经费支持
作者: 杨照玉*, 王加如, 李欣绪：山东第一医科大学(山东省医学科学院)，山东 济南；王志奎#, 籍文捷, 杨 雨, 翟文娟：临沂市人民医院，山东 临沂；张宏涛, 张静静：锦州医科大学，临沂市人民医院研究生培养基地，山东 临沂
关键词: 利妥昔单抗；特发性膜性肾病；抗磷脂酶A2受体抗体；研究进展；Rituximab； Idiopathic Membranous Nephropathy； Anti-PLA2 Rantibodies； Advances
摘要: 利妥昔单抗(rituximab, RTX)是一种针对表达于B淋巴细胞的CD20的人/鼠嵌合单克隆抗体，最初用于治疗淋巴瘤，但越来越多地用于治疗自身免疫性疾病。膜性肾病(membranous nephropathy, MN)是成人肾病综合征的常见病因，在大多数患者中，磷脂酶A2受体(phospholipase A2 receptor, PLA2R)作为靶抗原的鉴定显著改变了MN的治疗，并为B细胞耗竭剂(如RTX)提供了基本原理。RTX现在被认为是MN的一线治疗选择，特别是对于肾功能恶化的中度和高度风险的患者。其治疗特发性膜性肾病(idiopathic membranous nephropathy, IMN)的经验已近20年。在这篇综述中，我们概述了目前的文献中RTX治疗特发性膜性肾病的相关研究进展。
Abstract: Rituximab (RTX) is a human/mouse chimeric monoclonal antibody targeting CD20 expressed on B lymphocytes. It was initially used to treat lymphoma, but increasingly used to treat autoimmune diseases. Membrane nephropathy (membranous nephropathy, MN) is a common cause of adult ne-phrotic syndrome. In most patients, the identification of phospholipase A2 receptor (PLA2R) as a target antigen has significantly changed the treatment of MN and provided a basic rationale for B cell depletion agents (such as RTX). RTX is now considered as a first-line treatment option for MN, especially for patients with moderate and high risk of renal function deterioration. Its experience in treating idiopathic membranous nephropathy (IMN) has been nearly 20 years. In this review, we reviewed the current literature on RTX in the treatment of idiopathic membranous nephropathy.
文章引用：杨照玉, 王志奎, 王加如, 张宏涛, 张静静, 籍文捷, 杨雨, 翟文娟, 李欣绪. 利妥昔单抗用于特发性膜性肾病治疗的研究进展[J]. 临床医学进展, 2023, 13(2): 1517-1529. https://doi.org/10.12677/ACM.2023.132210

参考文献

[1] Lu, H., Shen, J., Sun, J. and Sun, J. (2022) Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis. Applied Bionics and Biomechanics, 2022, Article ID: 5393797. [Google Scholar] [CrossRef] [PubMed]
[2] Bomback, A.S. and Fervenza, F.C. (2018) Membranous Nephropathy: Approaches to Treatment. The American Journal of Nephrology, 47, 30-42. [Google Scholar] [CrossRef] [PubMed]
[3] Zhao, Q., Dai, H., Liu, X., et al. (2021) Helper T Cells in Idiopathic Mem-branous Nephropathy. Frontiers in Immunology, 12, Article ID: 665629. [Google Scholar] [CrossRef] [PubMed]
[4] 王涛, 李婷婷, 杨洪娟. 利妥昔单抗治疗特发性膜性肾病的研究进展[J]. 中华肾病研究电子杂志, 2017, 6(5): 228-232.
[5] Ronco, P., Plaisier, E. and Debiec, H. (2021) Ad-vances in Membranous Nephropathy. Journal of Clinical Medicine, 10, 607. [Google Scholar] [CrossRef] [PubMed]
[6] Scolari, F., Delbarba, E., Santoro, D., et al. (2021) Rituximab or Cyclo-phosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. Journal of the Ameri-can Society of Nephrology, 32, 972-982. [Google Scholar] [CrossRef] 
[7] Gauckler, P., Shin, J.I., Alberici, F., et al. (2021) Rituximab in Membranous Nephropathy. Kidney International, Ernational Reports, 6, 881-893. [Google Scholar] [CrossRef] [PubMed]
[8] Stai, S., Lioulios, G., Christodoulou, M., et al. (2022) From KDIGO 2012 towards KDIGO 2021 in Idiopathic Membranous nephropathy Guidelines: What Has Changed over the Last 10 Years? Journal of Nephrology. [Google Scholar] [CrossRef] [PubMed]
[9] Zhu, P., Zhou, F.D., Wang, S.X., et al. (2015) Increasing Fre-quency of Idiopathic Membranous Nephropathy in Primary Glomerular Disease: A 10-Year Renal Biopsy Study from a Single Chinese Nephrology Centre. Nephrology (Carlton), 20, 560-566. [Google Scholar] [CrossRef] [PubMed]
[10] Tang, L., Yao, J., Kong, X., et al. (2017) Increasing Prevalence of Mem-branous Nephropathy in Patients with Primary Glomerular Diseases: A Cross-Sectional Study in China. Nephrology (Carlton), 22, 168-173. [Google Scholar] [CrossRef] [PubMed]
[11] Xu, X., Wang, G., Chen, N., et al. (2016) Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. Journal of the American Society of Nephrology, 27, 3739-3746. [Google Scholar] [CrossRef] 
[12] Liu, Y., Xu, X., Xu, R. and Zhang, S. (2019) Renoprotective Ef-fects of Isoliquiritin against Cationic Bovine Serum Albumin-Induced Membranous Glomerulonephritis in Experimental Rat Model through Its Anti-Oxidative and Anti-Inflammatory Properties. Drug Design, Development and Therapy, 13, 3735-3751. [Google Scholar] [CrossRef] 
[13] Wu, L., Lai, J., Ling, Y., et al. (2021) A Review of the Current Prac-tice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China. Medical Science Monitor, 27, e930097. [Google Scholar] [CrossRef] 
[14] Claudio, P. (2022) Primary Membranous Nephropathy: An Endless Story. Journal of Nephrology. [Google Scholar] [CrossRef] [PubMed]
[15] 张婕, 何伟春, 抗CD20单克隆抗体治疗特发性膜性肾病的研究进展[J]. 中国医药, 2021, 16(7): 1104-1107.
[16] Ruggenenti, P., Fervenza, F.C. and Remuzzi, G. (2017) Treat-ment of Membranous Nephropathy: Time for a Paradigm Shift. Nature Reviews Nephrology, 13, 563-579. [Google Scholar] [CrossRef] [PubMed]
[17] Ronco, P., Beck, L., Debiec, H., et al. (2021) Membranous Nephrop-athy. Nature Reviews Disease Primers, 7, 69. [Google Scholar] [CrossRef] [PubMed]
[18] Beck, L.H., Bonegio, R.G., Lambeau, G., et al. (2009) Salant, M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. The New England Journal of Medicine, 361, 11-21. [Google Scholar] [CrossRef] 
[19] Chen, M., Zhang, X., Xiong, Y. and Xu, G. (2022) Efficacy of Low or Heavy Rituximab-Based Protocols and Comparison with Seven Regimens in Idiopathic Membranous Nephropathy: A Systematic Review and Network Meta- Analysis. International Urology and Nephrology. [Google Scholar] [CrossRef] [PubMed]
[20] Sethi, S., Debiec, H., Madden, B., et al. (2020) Neural Epidermal Growth Factor-Like 1 Protein (NELL-1) Associated Membranous Nephropathy. Kidney International, Ernational, 97, 163-174. [Google Scholar] [CrossRef] [PubMed]
[21] 陈梦星, 张丽华, 刘志红, 利妥昔单抗在特发性膜性肾病治疗中的应用[J]. 肾脏病与透析肾移植杂志, 2018, 27(3): 274-278+293.
[22] Marshall, M.J.E., Stopforth, R.J. and Cragg, M.S. (2017) Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Frontiers in Immunology, 8, 1245. [Google Scholar] [CrossRef] [PubMed]
[23] Pierpont, T.M., Limper, C.B. and Richards, K.L. (2018) Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy. Frontiers in Oncology, 8, 163. [Google Scholar] [CrossRef] [PubMed]
[24] 王晓菲, 张婷, 刘寻, 逯小英, 邹洪斌, 利妥昔单抗治疗原发性肾病综合征的研究进展[J]. 中国医药, 2021, 16(3): 473-476.
[25] Passerini, P., Malvica, S., Tripodi, F., et al. (2019) Membranous Nephropathy (MN) Recurrence after Renal Transplantation. Fron-tiers in Immunology, 10, 1326. [Google Scholar] [CrossRef] [PubMed]
[26] 潘登, 李艳. 利妥昔单抗注射液作用机制及临床应用的研究进展[J]. 医学综述, 2015, 21(11): 2025-2027.
[27] 卢婉君, 龚书豪, 李娟, 王缨. 利妥昔单抗在特发性膜性肾病中应用的研究进展[J]. 实用临床医学, 2020, 21(1): 99-102+107.
[28] 原小童, 于为民, 任小军. 利妥昔单抗用于特发性膜性肾病的研究[J]. 系统医学, 2017, 2(21): 166-168.
[29] Roccatello, D., Sciascia, S., Di Simone, D. et al. (2016) New Insights into Immune Mechanisms Underlying Response to Rituximab in Patients with Membranous Nephropathy: A Prospective Study and a Review of the Literature. Autoimmunity Reviews, 15, 529-538. [Google Scholar] [CrossRef] [PubMed]
[30] 刘梓, 胡志娟. 利妥昔单抗在肾脏病中的应用[J]. 临床肾脏病杂志, 2021, 21(1): 78-82.
[31] 朱博韬, 郑丹侠. 利妥昔单抗治疗特发性膜性肾病的研究进展[J]. 国际泌尿系统杂志, 2022, 42(1): 172-175.
[32] Remuzzi, G., Chiurchiu, C., Abbate, M., et al. (2002) Rituximab for Idi-opathic Membranous Nephropathy. The Lancet, 360, 923-924. [Google Scholar] [CrossRef] 
[33] Fervenza, F.C., Cosio, F.G., Erickson, S.B., et al. (2008) Rituximab Treatment of Idiopathic Membranous Nephropathy. Kidney International, 73, 117-125. [Google Scholar] [CrossRef] [PubMed]
[34] Ruggenenti, P., Cravedi, P., Chianca, A., et al. (2012) Rituximab in Idi-opathic Membranous Nephropathy. Journal of the American Society of Nephrology, 23, 1416-1425. [Google Scholar] [CrossRef] 
[35] Dahan, K., Debiec, H., Plaisier, E., et al. (2017) Rituximab for Se-vere Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Neph-rology, 28, 348-358. [Google Scholar] [CrossRef] 
[36] Wang, X., Cui, Z., Zhang, Y.M., et al. (2018) Rituximab for Non-Responsive Idiopathic Membranous Nephropathy in a Chinese Cohort. Nephrology Dialysis Transplantation, 33, 1558-1563. [Google Scholar] [CrossRef] [PubMed]
[37] Waldman, M., Beck, L.H., Braun, M., et al. (2016) Membra-nous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab. Kidney International Re-ports, 1, 73-84. [Google Scholar] [CrossRef] [PubMed]
[38] Cortazar, F.B., Leaf, D.E., Owens, C.T., et al. (2017) Niles, Combination Therapy with Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Idiopathic Membranous Nephropathy: A Case Series. BMC Nephrology, 18, 44. [Google Scholar] [CrossRef] [PubMed]
[39] Fervenza, F.C., Appel, G.B., Barbour, S.J., et al. (2019) Rituxi-mab or Cyclosporine in the Treatment of Membranous Nephropathy. The New England Journal of Medicine, 381, 36-46. [Google Scholar] [CrossRef] 
[40] Ruggenenti, P. and Remuzzi, G. (2019) A First Step toward a New Approach to Treating Membranous Nephropathy. The New England Journal of Medicine, 381, 86-88. [Google Scholar] [CrossRef] 
[41] Lu, W., Gong, S., Li, J., et al. (2020) Efficacy and Safety of Rituxi-mab in the Treatment of Membranous Nephropathy: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 99, e19804. [Google Scholar] [CrossRef] 
[42] Cravedi, P., Remuzzi, G. and Ruggenenti, P. (2014) Rituxi-mab in Primary Membranous Nephropathy: First-Line Therapy, Why Not? Nephron Clinical Practice, 128, 261-269. [Google Scholar] [CrossRef] [PubMed]
[43] Row, P.G., Cameron, J.S., Turner, D.R., et al. (1975) Membranous Nephropathy. Long-Term Follow-Up and Association with Neoplasia. QJM: An International Journal of Medicine, 44, 207-239.
[44] Polanco, N., Gutierrez, E., Covarsi, A., et al. (2010) Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 21, 697-704. [Google Scholar] [CrossRef] 
[45] Sprangers, B., Bomback, A.S., Cohen, S.D., et al. (2012) Idio-pathic Membranous Nephropathy: Clinical and Histologic Prognostic Features and Treatment Patterns over Time at a Ter-tiary Referral Center. The American Journal of Nephrology, 36, 78-89. [Google Scholar] [CrossRef] [PubMed]
[46] Bomback, A.S., Perazella, M.A. and Choi, M.J. (2015) American Society of Nephrology Quiz and Questionnaire 2014: Glomerular Diseases. Clinical Journal of the American Society of Neph-rology, 10, 716-722. [Google Scholar] [CrossRef] 
[47] Fervenza, F.C., Sethi, S. and Specks, U. (2008) Idiopathic Membra-nous Nephropathy: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology, 3, 905-919. [Google Scholar] [CrossRef] 
[48] Cattran, D.C., Pei, Y., Greenwood, C.M., et al. (1997) Validation of a Predictive Model of Idiopathic Membranous Nephropathy: Its Clinical and Research Implications. Kidney International, 51, 901-907. [Google Scholar] [CrossRef] [PubMed]
[49] Cattran, D.C., Kim, E.D., Reich, H., et al. (2017) Membranous Nephrop-athy: Quantifying Remission Duration on Outcome. Journal of the American Society of Nephrology, 28, 995-1003. [Google Scholar] [CrossRef] 
[50] Yamaguchi, M. ando, M., Katsuno, T., et al. (2018) Urinary Protein and Renal Prognosis in Idiopathic Membranous Nephropathy: A Multicenter Retrospective Cohort Study in Japan. Renal Failure, 40, 435-441. [Google Scholar] [CrossRef] 
[51] Horvatic, I., Ljubanovic, D.G., Bulimbasic, S., et al. (2012) Prognostic Significance of Glomerular and Tubulointerstitial Morphometry in Idiopathic Membranous Nephropathy. Pa-thology Research and Practice, 208, 662-667. [Google Scholar] [CrossRef] [PubMed]
[52] Zuo, K., Wu, Y., Li, S.J., et al. (2013) Long-Term Outcome and Prognostic Factors of Idiopathic Membranous Nephropathy in the Chinese Population. Clinical Nephrology, 79, 445-453. [Google Scholar] [CrossRef] 
[53] Ponticelli, C., Zucchelli, P., Passerini, P., et al. (1995) A 10-Year Fol-low-Up of a Randomized Study with Methylprednisolone and Chlorambucil in Membranous Nephropathy. Kidney In-ternational, 48, 1600-1604. [Google Scholar] [CrossRef] [PubMed]
[54] McQuarrie, E.P., Stirling, C.M. and Geddes, C.C. (2012) Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Outcome in the Era of Evidence-Based Therapy. Nephrology Dial-ysis Transplantation, 27, 235-242. [Google Scholar] [CrossRef] [PubMed]
[55] Chembo, C.L., Marshall, M.R., Williams, L.C., et al. (2015) Long-Term Outcomes for Primary Glomerulonephritis: New Zealand Glomerulonephritis Study. Nephrology (Carlton), 20, 899-907. [Google Scholar] [CrossRef] [PubMed]
[56] Bae, E., Lee, S.W., Park, S., et al. (2018) Treatment and Clinical Outcomes of Elderly Idiopathic Membranous Nephropathy: A Multicenter Cohort Study in Korea. Archives of Gerontology and Geriatrics, 76, 175-181. [Google Scholar] [CrossRef] [PubMed]
[57] Donadio, J.V., Torres, V.E., Velosa, J.A., et al. (1988) Idio-pathic Membranous Nephropathy: The Natural History of Untreated Patients. Kidney International, 33, 708-715. [Google Scholar] [CrossRef] [PubMed]
[58] He, H.G., Wu, C.Q., Ye, K., et al. (2019) Focal Segmental Glomeruloscle-rosis, Excluding Atypical Lesion, Is a Predictor of Renal Outcome in Patients with Membranous Nephropathy: A Retro-spective Analysis of 716 Cases. BMC Nephrology, 20, 328. [Google Scholar] [CrossRef] [PubMed]
[59] Troyanov, S., Roasio, L., Pandes, M., et al. (2006) Renal Pathol-ogy in Idiopathic Membranous Nephropathy: A New Perspective. Kidney International, 69, 1641-1648. [Google Scholar] [CrossRef] [PubMed]
[60] 陈东溟. 利妥昔单抗治疗激素和环磷酰胺抵抗的微小病变型肾病综合征达到长期完全缓解相关病例回顾和总结[J]. 实用药物与临床, 2017, 20(3): 298-300.
[61] van Vollenhoven, R.F., Emery, P., Bingham, C.O., et al. (2010) Long-Term Safety of Patients Receiving Rituximab in Rheumatoid Arthri-tis Clinical Trials. The Journal of Rheumatology, 37, 558-567. [Google Scholar] [CrossRef] [PubMed]
[62] Kronbichler, A., Windpessl, M., Pieringer, H., et al. (2017) Rituximab for Immunologic Renal Disease: What the Nephrologist Needs to Know. Autoimmunity Reviews, 16, 633-643. [Google Scholar] [CrossRef] [PubMed]
[63] Focosi, D., Tuccori, M. and Maggi, F. (2019) Progressive Mul-tifocal Leukoencephalopathy and Anti-CD20 Monoclonal Antibodies: What Do We Know after 20 Years of Rituximab. Reviews in Medical Virology, 29, e2077. [Google Scholar] [CrossRef] [PubMed]
[64] 廖建, 朱彩风, 包自阳, 郭莹, 李成林. 利妥昔单抗治疗特发性膜性肾病的研究及进展[J]. 中国中西医结合肾病杂志, 2017, 18(9): 844-846.
[65] Loomba, R. and Liang, T.J. (2017) Hep-atitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Man-agement Strategies, and Future Directions. Gastroenterology, 152, 1297-1309. [Google Scholar] [CrossRef] [PubMed]
[66] Alzayer, H., Sebastian, K.K. and O’Shaughnessy, M.M. (2022) Rituximab Dosing in Glomerular Diseases: A Scoping Review. Canadian Journal of Kidney Health and Disease, 9, 1-18. [Google Scholar] [CrossRef] [PubMed]
[67] Ahmadian, E., Khatibi, S.M.H., Vahed, S.Z. and Ardalan, M. (2022) Novel Treatment Options in Rituximab-Resistant Membranous Nephropathy Patients. International Im-munopharmacology, 107, Article ID: 108635. [Google Scholar] [CrossRef] [PubMed]

为你推荐